MedicalResearch.com Interview with:
Dr Ranjit Manchanda MD, MRCOG, PhDProfessor & Consultant Gynaecological OncologistNHS Innovation Accelerator (NIA) FellowIntegrated Academic Training Programme DirectorLondon Specialty School of Obstetrics & Gynaecology, Health Education EnglandCancer Research UK, Barts Centre | Queen Mary University of LondonDepartment of Gynaecological Oncology | Barts Health NHS Trust, Royal London HospitalLondon
MedicalResearch.com: What is the background for this study?
Response: Current national and international guidelines recommend genetic-testing (for BRCA genes) in women with breast cancer (BC) who fulfil recognised/established clinical criteria which are based on a history of cancer in the patient and family. However 50% of BRCA carriers do not fulfil these criteria. Thus the current family-history or clinical-criteria based approach misses half the people at risk. Additionally only 20%-30% of patients eligible tend to get referred for and access BRCA testing. Newer genes like PALB2 which cause breast cancer have been identified and can also be tested for.
Knowing a patients mutation status (carrier identification) can have a number of benefits. After unilateral breast cancer, mutations carriers can choose contralateral prophylactic-mastectomy (CPM) or preventative mastectomy of the second breast to reduce their risk of developing contralateral breast cancer. Additionally they can opt for surgical prevention for ovarian-cancer (OC). Cancer affected carriers may become eligible for novel drugs (like poly-adenosine-diphosphate-ribose-polymerase (PARP) inhibitors) and other precision-medicine based novel drug therapies through clinical trials. A major advantage of genetic-testing is enabling testing relatives of breast cancer mutation carriers, to identify unaffected relatives carrying mutations who can benefit from early diagnosis and cancer prevention.
Testing everyone instead of being restricted by family history will identify many more mutation carriers and their family members who can benefit from precision prevention. A large proportion of these cancers are preventable in known unaffected mutations carriers.
MedicalResearch.com: What are the main findings?
Response: In our study we compare two strategies of genetic testing in women with breast cancer.
Strategy-1: All women with breast cancer undergo BRCA1/BRCA2/PALB2 testing (multi gene testing).
Strategy-2: This is current practice where only those women who fulfil current family-history based clinical-criteria undergo BRCA-testing.
For the first time we show that moving to a strategy for multigene testing for all women with breast cancer diagnosed annually (irrespective of family history or any criteria) can prevent an additional 1142 breast cancer and 959 ovarian cancer cases and 633 (breast/ovarian cancer) deaths in the UK; and prevent 5,478 breast cancer and 4,275 ovarian cancer cases and 2,406 (breast/ovarian cancer) deaths in the USA.
We have performed a comprehensive cost-effectiveness analysis and show that this new strategy would remain well below UK/NICE (National Institute of Health & Care Excellence) and US cost-effectiveness thresholds which are 20,000-30,000/QALY (quality adjusted life year) and $100,000/QALY respectively. The incremental cost-effectiveness ratios are 10,464/QALY (from a payer-perspective) or 7,216/QALY (from a societal-perspective) in the UK or $65,661/QALY (form a payer-perspective) or $61,618/QALY (from a societal-perspective) in USA women.
MedicalResearch.com: What should readers take away from your report?
Response: Our findings support changing current policy to expand genetic-testing to multigene testing (BRCA1, BRCA2 and PALB2 mutations) for all women with breast cancer. This approach will save many more lives and is cost-effective.
A similar approach has recently been implemented for ovarian cancer over the last few years and now we need to do it in breast cancer too.
Oncologists, surgeons and clinical nurse-specialists may need to provide pre-test counselling and genetic-testing, with genetic-services focusing on post-test counselling and support for women found to carry gene mutations. Such a model has been implemented in ovarian cancer pathways. There are other models too which have been successfully used to deliver genetic testing and counselling in ovarian cancer and can be extrapolated or explored for breast cancer. Implementation will need to be accompanied by a process of training and education for relevant clinicians/health professionals involved in the breast cancer care pathway so that they can understand the implications for management.
Costs of testing are falling and technological advances can now deliver large volume high throughput genetic testing. All this provides huge new opportunities for cancer prevention and changes in the way we deliver cancer genetic testing in health care. This approach can ensure that more women can take preventative action to minimise their future cancer risk through prevention or early diagnosis options.
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: What is needed is development and evaluation of implementation models and pathways to deliver this. Newer context specific delivery models will be needed for implementing this approach.
We are interested in evaluating and undertaking analysis in other countries too and also in the development and evaluation of context specific implementation pathways for unselected testing at breast cancer diagnosis including in low and middle income countries.
Disclosures these are listed in the paper. Please see paper.
I have received research funding from The Eve Appeal and Cancer Research UK into population testing and from Barts & the London Charity and Rosetree Charity outside this work, as well as an honorarium for grant review from Israel National Institute for Health Policy Research and honorarium for advisory board meeting for MSD and Astrazeneca. My work is supported through a NHS Innovation Accelerator Fellowship.
Disclosures from other co-authors-
Dr Buist and Dr Bowels- Grants from NCI. Dr Evans- Honorarium from Astrazeneca and grants from Manchester National Institute of Health Research Biomedical Research Centre. Dr Eccles- Grants from Cancer Research UK. Dr Cuzick and Dr Brentnall- Grants from Cancer Research UK.
Citation:
Sun L, Brentnall A, Patel S, et al. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.JAMA Oncol.Published online October 03, 2019. doi:10.1001/jamaoncol.2019.3323
[wysija_form id=3]
Oct 4, 2019 @ 1:48 pm
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Post Views: 178
Continued here:
Study Finds Multigene Testing For All Women With Breast Cancer Can Save Lives and Money - MedicalResearch.com
- F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent [Last Updated On: April 15th, 2010] [Originally Added On: April 15th, 2010]
- F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent [Last Updated On: April 15th, 2010] [Originally Added On: April 15th, 2010]
- GSK, MedTrust launch iPhone/iPad app for cancer trials [Last Updated On: June 11th, 2010] [Originally Added On: June 11th, 2010]
- GSK, MedTrust launch iPhone/iPad app for cancer trials [Last Updated On: June 11th, 2010] [Originally Added On: June 11th, 2010]
- 22 Million Australian Cloud computing initiative to benefit life science researchers [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- GE Healthcare announces SaaS Electronic Medical Records Management [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- 22 Million Australian Cloud computing initiative to benefit life science researchers [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- GE Healthcare announces SaaS Electronic Medical Records Management [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- How useful would be the Single-patient clinical trials for improving the hopes of Personalized medicine [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- How useful would be the Single-patient clinical trials for improving the hopes of Personalized medicine [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- Life Sciences at Oracle Open World 2010 [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- ChIP Enrichment Analysis can speed up drug discovery [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- GE’s healthymagination initiative lead Smart Patient Room to improve patient safety goes live at Bassett Medical Center [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- The SaaS impact on solution selling for ISVs (via Inner Lining) [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- Oracle starts the Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 70% of Pharmaceutical organisations outsource at least one PV activity. This level is expected to increase to 80% by 2012 [Last Updated On: October 26th, 2010] [Originally Added On: October 26th, 2010]
- Insurance coverage for healthcare IT software, to protect healthcare IT companies from damages inflicted by their software [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- India announce Heart Surgery for $1000 USD [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- Indian Healthcare IT market & Oracle’s presence in Indian Healthcare [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- Insurance coverage for healthcare IT software, to protect healthcare IT companies from damages inflicted by their software [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- India announce Heart Surgery for $1000 USD [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- Indian Healthcare IT market & Oracle’s presence in Indian Healthcare [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- Harvard Medical Schools new automated safety surveillance system provides faster early warnings in the postmarket evaluation of medical device safety [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- SalesForce.com partner introduces CRM for clinical trial management on Force Platform [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- Widespread fraud in the Clinical Trial of Drugs is pervasive event in United States [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- Scott Stern Kellogg School of Management speaks about “New Drug Development: From Laboratory to Blockbuster to Generic,” [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- MNC Pharma tries to capture the $1.9 billion Indian OTC market by selling Drugs through India’s 170000 post offices [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- collaborative clinical trials management software for Central Laboratories [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- Clinical Trial and Pharmacovigilance process automation [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- Microsoft in Clinical Trials Management System (CTMS) and Electronic Data Capture (EDC) [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- Oracle Business Intelligence Enteprise Edition (OBIEE) for Clinical Trial Management System (CTMS) [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- trends in the life sciences and pharma research and development outsourcing (RDO) [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- Sanofi-Aventis ties up with Oxford Univ for oncology research in India [Last Updated On: December 20th, 2010] [Originally Added On: December 20th, 2010]
- PharmaNet unveils touch screen capable data capture platform for Phase I Clinical Trials [Last Updated On: December 20th, 2010] [Originally Added On: December 20th, 2010]
- Adverse Events in Hospitals- United States Department of Health Report slams current measures in US hospitals [Last Updated On: December 21st, 2010] [Originally Added On: December 21st, 2010]
- IBM Files Application to Patent The Patent [Last Updated On: January 4th, 2011] [Originally Added On: January 4th, 2011]
- How to improve R&D productivity: the pharmaceutical industry’s grand challenge [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- AstraZeneca Announce Real-World Evidence Data Collaboration [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- How to improve R&D productivity: the pharmaceutical industry’s grand challenge [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- AstraZeneca Announce Real-World Evidence Data Collaboration [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- Medication adherence improves, When Patients Share Their Stories [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- Questions for the CRO [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- Clinical Research Sites Struggle With Increasing Trial Complexity yet most depend on, Google (or other search sites) as the primary information tool [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- Medication adherence improves, When Patients Share Their Stories [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- Questions for the CRO [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- Clinical Research Sites Struggle With Increasing Trial Complexity yet most depend on, Google (or other search sites) as the primary information tool [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- Law of the land can help or destroy the Pharmacovigilance system [Last Updated On: March 27th, 2011] [Originally Added On: March 27th, 2011]
- Law of the land can help or destroy the Pharmacovigilance system [Last Updated On: March 27th, 2011] [Originally Added On: March 27th, 2011]
- Coast To Coast AM - 15.11.2011 - 1/4 - Regenerative Medicine/Dulce Base - Video [Last Updated On: November 29th, 2011] [Originally Added On: November 29th, 2011]
- Coast To Coast AM - 15.11.2011 - 4/4 - Regenerative Medicine/Dulce Base - Video [Last Updated On: November 29th, 2011] [Originally Added On: November 29th, 2011]
- HIV Resistant Genes...Rhesus Negative, Excess PK [Last Updated On: November 30th, 2011] [Originally Added On: November 30th, 2011]
- Indian Government’s new dose of strong medicine to bring cheers to Foreign Pharma CEOs who cut their teeth by struggling to convince Indian pharma to change sales practices [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Indian Government’s new dose of strong medicine to bring cheers to Foreign Pharma CEOs who cut their teeth by struggling to convince Indian pharma to change sales practices [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Drug Reps Soften Their Sales Pitches, as pharma learns from Disney [Last Updated On: January 15th, 2012] [Originally Added On: January 15th, 2012]
- Drug Reps Soften Their Sales Pitches, as pharma learns from Disney [Last Updated On: January 15th, 2012] [Originally Added On: January 15th, 2012]
- Oracle Unveils Oracle® Health Sciences Omics Data Bank as Part of Oracle Health Sciences Translational Research Center [Last Updated On: January 29th, 2012] [Originally Added On: January 29th, 2012]
- Oracle Unveils Oracle® Health Sciences Omics Data Bank as Part of Oracle Health Sciences Translational Research Center [Last Updated On: January 29th, 2012] [Originally Added On: January 29th, 2012]
- One Way to Teach Your Boss About Social Media [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- “The Banks Can Do It, Why Can’t Hospitals?” [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- Internet on any Display Device, or internet on TV at low cost can it transform Healthcare or Clinical Research [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- Is Life Sciences the New Frontier for Analytics? [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- Internet on any Display Device, or internet on TV at low cost can it transform Healthcare or Clinical Research [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- Is Life Sciences the New Frontier for Analytics? [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- Regenerative Medicine: Current Concepts and Changing Trends - Video [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- bluebird bio Appoints David Davidson, M.D., as Chief Medical Officer [Last Updated On: February 16th, 2012] [Originally Added On: February 16th, 2012]
- privacy controlled social networking to connect patients with caregivers [Last Updated On: February 19th, 2012] [Originally Added On: February 19th, 2012]
- SOCIAL CRM and its Impact on Pharmaceutical Industry [Last Updated On: February 19th, 2012] [Originally Added On: February 19th, 2012]
- SOCIAL CRM and its Impact on Pharmaceutical Industry [Last Updated On: February 19th, 2012] [Originally Added On: February 19th, 2012]
- privacy controlled social networking to connect patients with caregivers [Last Updated On: February 19th, 2012] [Originally Added On: February 19th, 2012]
- British Government launches Government Cloud Store with 257 Cloud Computing Suppliers [Last Updated On: February 26th, 2012] [Originally Added On: February 26th, 2012]
- Patient Adherence Investments by Pharma Companies Current Scenario [Last Updated On: February 26th, 2012] [Originally Added On: February 26th, 2012]
- Pharma looks to mobile strategies to effectively reach prescribers | mHIMSS [Last Updated On: February 26th, 2012] [Originally Added On: February 26th, 2012]
- British Government launches Government Cloud Store with 257 Cloud Computing Suppliers [Last Updated On: February 26th, 2012] [Originally Added On: February 26th, 2012]
- Pharma looks to mobile strategies to effectively reach prescribers | mHIMSS [Last Updated On: February 26th, 2012] [Originally Added On: February 26th, 2012]
- Patient Adherence Investments by Pharma Companies Current Scenario [Last Updated On: February 26th, 2012] [Originally Added On: February 26th, 2012]
- Predictive Analytics for Patient Adherence [Last Updated On: March 4th, 2012] [Originally Added On: March 4th, 2012]
- Predictive Analytics for Patient Adherence [Last Updated On: March 4th, 2012] [Originally Added On: March 4th, 2012]
- Genetic manipulation boosts growth of brain cells linked to learning, enhances effects of antidepressants [Last Updated On: March 10th, 2012] [Originally Added On: March 10th, 2012]
- Can “Clinical Data Integration on the Cloud” be a reality? [Last Updated On: March 11th, 2012] [Originally Added On: March 11th, 2012]
- Can “Clinical Data Integration on the Cloud” be a reality? [Last Updated On: March 11th, 2012] [Originally Added On: March 11th, 2012]